By: IPP Bureau
Last updated : August 01, 2026 1:16 am
The company's EBITDA grew 33.5% year-on-year to Rs. 93.1 crore, with the EBITDA margin expanding to 22.0%, an improvement of 190 basis points over the corresponding quarter last year
CORONA Remedies Ltd. reported a strong performance for the first quarter of FY27, with revenue from operations increasing 21.9% year-on-year to Rs. 422.4 crore, driven by robust brand-building initiatives and operational excellence.
Profit after tax (PAT) rose 30.1% to Rs. 60.1 crore, while the PAT margin improved by 90 basis points to 14.2%.
The company's EBITDA grew 33.5% year-on-year to Rs. 93.1 crore, with the EBITDA margin expanding to 22.0%, an improvement of 190 basis points over the corresponding quarter last year.
Nirav K. Mehta, Managing Director and CEO of CORONA Remedies, said the first quarter reflected the company's commitment to consistent growth through operational excellence and focused brand building.
Mehta noted that strong revenue growth and an improvement in market ranking demonstrate the effectiveness of the company's strategy.
Mehta added that CORONA will continue to strengthen its focus on core therapy areas, including women's healthcare, cardio-diabetes, pain management and urology, while expanding its presence in the infertility and biosimilars segments.
During the quarter, CORONA continued to outperform the Indian Pharmaceutical Market (IPM), remaining the fastest-growing company among the top 30 pharmaceutical companies for the sixth consecutive month, according to MAT June 2026 data.
The company improved its market ranking by three positions over the past year to reach the 26th position and retained its fifth rank in the gynaecology segment.
The company also inaugurated and commenced commercialisation of its EU-GMP-approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026. In addition, it initiated the integration of the recently acquired Wokadine brand across supply chain and distribution operations.